284 related articles for article (PubMed ID: 21478273)
1. Endogenous Myc maintains the tumor microenvironment.
Sodir NM; Swigart LB; Karnezis AN; Hanahan D; Evan GI; Soucek L
Genes Dev; 2011 May; 25(9):907-16. PubMed ID: 21478273
[TBL] [Abstract][Full Text] [Related]
2. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
3. MYC needs MNT.
Link JM; Hurlin PJ
Cell Cycle; 2013 Feb; 12(3):385-6. PubMed ID: 23324353
[No Abstract] [Full Text] [Related]
4. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
[TBL] [Abstract][Full Text] [Related]
5. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
[TBL] [Abstract][Full Text] [Related]
6. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.
Si J; Yu X; Zhang Y; DeWille JW
Mol Cancer; 2010 Apr; 9():92. PubMed ID: 20426839
[TBL] [Abstract][Full Text] [Related]
7. The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
Kumaraswamy A; Mamidi A; Desai P; Sivagnanam A; Perumalsamy LR; Ramakrishnan C; Gromiha M; Rajalingam K; Mahalingam S
J Biol Chem; 2018 Oct; 293(40):15691-15705. PubMed ID: 30139745
[No Abstract] [Full Text] [Related]
8. An MXD1-derived repressor peptide identifies noncoding mediators of MYC-driven cell proliferation.
Raffeiner P; Hart JR; García-Caballero D; Bar-Peled L; Weinberg MS; Vogt PK
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6571-6579. PubMed ID: 32156728
[TBL] [Abstract][Full Text] [Related]
9. Of Myc and Mnt.
Hooker CW; Hurlin PJ
J Cell Sci; 2006 Jan; 119(Pt 2):208-16. PubMed ID: 16410546
[TBL] [Abstract][Full Text] [Related]
10. Oncogene addiction to c-MYC in myeloma cells.
Holien T; Sundan A
Oncotarget; 2012 Aug; 3(8):739-40. PubMed ID: 22964579
[No Abstract] [Full Text] [Related]
11. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription.
Struntz NB; Chen A; Deutzmann A; Wilson RM; Stefan E; Evans HL; Ramirez MA; Liang T; Caballero F; Wildschut MHE; Neel DV; Freeman DB; Pop MS; McConkey M; Muller S; Curtin BH; Tseng H; Frombach KR; Butty VL; Levine SS; Feau C; Elmiligy S; Hong JA; Lewis TA; Vetere A; Clemons PA; Malstrom SE; Ebert BL; Lin CY; Felsher DW; Koehler AN
Cell Chem Biol; 2019 May; 26(5):711-723.e14. PubMed ID: 30880155
[TBL] [Abstract][Full Text] [Related]
13. Drosophila Myc: A master regulator of cellular performance.
Grifoni D; Bellosta P
Biochim Biophys Acta; 2015 May; 1849(5):570-81. PubMed ID: 25010747
[TBL] [Abstract][Full Text] [Related]
14. The MYCL and MXD1 transcription factors regulate the fitness of murine dendritic cells.
Anderson DA; Murphy TL; Eisenman RN; Murphy KM
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4885-4893. PubMed ID: 32071205
[TBL] [Abstract][Full Text] [Related]
15. A dynamic exchange of TCF3 and TCF4 transcription factors controls MYC expression in colorectal cancer cells.
Shah M; Rennoll SA; Raup-Konsavage WM; Yochum GS
Cell Cycle; 2015; 14(3):323-32. PubMed ID: 25659031
[TBL] [Abstract][Full Text] [Related]
16. Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes.
Yang H; Li TW; Ko KS; Xia M; Lu SC
Hepatology; 2009 Mar; 49(3):860-70. PubMed ID: 19086036
[TBL] [Abstract][Full Text] [Related]
17. The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics.
McAnulty J; DiFeo A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322239
[No Abstract] [Full Text] [Related]
18. Myc, Max, and Mnt: molecular mechanisms of enhancement of cholangiocarcinogenesis by cholestasis.
Nakamura I; Roberts LR
Gastroenterology; 2011 Jul; 141(1):32-4. PubMed ID: 21620848
[No Abstract] [Full Text] [Related]
19. MYC on the path to cancer.
Dang CV
Cell; 2012 Mar; 149(1):22-35. PubMed ID: 22464321
[TBL] [Abstract][Full Text] [Related]
20. Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression.
Frenzel A; Zirath H; Vita M; Albihn A; Henriksson MA
PLoS One; 2011; 6(11):e27988. PubMed ID: 22132187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
